2,3-二氯苯乙酸甲酯 | 10328-87-7

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,3-二氯苯乙酸甲酯
• 中文别名: 2,3-二氯苯基乙酸甲酯
• 英文名称: methyl 2-(2,3-dichlorophenyl)acetate
• 英文别名: Methyl 2,3-dichlorophenylacetate
• CAS: 10328-87-7
• 化学式: C₉H₈Cl₂O₂
• 分子量: 219.067
• InChiKey: XUMYFVFSYKMRDF-UHFFFAOYSA-N

物化性质

• 沸点：
  274.5±25.0 °C(Predicted)
• 密度：
  1.318±0.06 g/cm3(Predicted)
• 稳定性/保质期：
  遵照规格使用和储存则不会分解。

计算性质

• 辛醇/水分配系数(LogP)：
  3
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.22
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2916399090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335

SDS

Name:	Methyl 2,3-dichlorophenylacetate Material Safety Data Sheet
Synonym:
CAS:	10328-87-7

Section 1 - Chemical Product MSDS Name: Methyl 2,3-dichlorophenylacetate Material Safety Data Sheet
Synonym:

---

SECTION 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
10328-87-7	Methyl 2,3-dichlorophenylacetate		unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

SECTION 3 - HAZARDS IDENTIFICATION EMERGENCY OVERVIEW Not available. Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

SECTION 4 - FIRST AID MEASURES
Eyes:
Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

SECTION 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

SECTION 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container. Vacuum or sweep up material and place into a suitable disposal container.

---

SECTION 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.

---

SECTION 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low. Exposure Limits CAS# 10328-87-7: Personal Protective Equipment
Eyes:
Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

SECTION 9 - PHYSICAL AND CHEMICAL PROPERTIES
Physical State: Solid or liquid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C9H8Cl2O2
Molecular Weight: 219.07

---

SECTION 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Hydrogen chloride, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

SECTION 11 - TOXICOLOGICAL INFORMATION RTECS#: CAS# 10328-87-7 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Methyl 2,3-dichlorophenylacetate - Not listed by ACGIH, IARC, or NTP.

---

SECTION 12 - ECOLOGICAL INFORMATION

---

SECTION 13 - DISPOSAL CONSIDERATIONS Dispose of in a manner consistent with federal, state, and local regulations.

---

SECTION 14 - TRANSPORT INFORMATION IATA Not regulated as a hazardous material. IMO Not regulated as a hazardous material. RID/ADR Not regulated as a hazardous material.

---

SECTION 15 - REGULATORY INFORMATION European/International Regulations European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases: S 24/25 Avoid contact with skin and eyes. WGK (Water Danger/Protection) CAS# 10328-87-7: No information available. Canada None of the chemicals in this product are listed on the DSL/NDSL list. CAS# 10328-87-7 is not listed on Canada's Ingredient Disclosure List. US FEDERAL TSCA CAS# 10328-87-7 is not listed on the TSCA inventory. It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
MSDS Creation Date: 6/10/2003 Revision #0 Date: Original. The information above is believed to be accurate and represents the best information currently available to us. However, we make no warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular purposes. In no way shall the company be liable for any claims, losses, or damages of any third party or for lost profits or any special, indirect, incidental, consequential or exemplary damages, howsoever arising, even if the company has been advised of the possibility of such damages.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,3-二氯苯乙酸甲酯 在 silver hexafluoroantimonate 、 carbonyl(pentamethylcyclopentadienyl)cobalt diiodide 、 水 、 sodium acetate 、 四丁基硫酸氢铵 、 potassium carbonate 、 lithium hydroxide 作用下， 以 四氢呋喃 、 甲苯 为溶剂， 反应 21.0h， 生成 3-(2,3-dichlorophenyl)furan-2(5H)-one
  参考文献：
  名称：

  钴催化乙烯基 C–H 添加到甲醛：从丙烯酸和 HCHO 合成丁烯内酯

  摘要：

  描述了用甲醛对丙烯酸进行羧基辅助的 C-H 官能化以得到丁烯内酯。这是首次通过钴催化的 C-H 活化将惰性乙烯基 C-H 键添加到甲醛中。与相关的 Rh 或 Ir 催化剂相比，观察到钴物种的独特反应性。γ-羟甲基化丁烯内酯是通过Na 2 CO 3在一锅催化反应后处理制备的。

  DOI：

  10.1021/acs.orglett.1c03095

文献信息

• Design of pyrido[2,3-d]pyrimidin-7-one inhibitors of receptor interacting protein kinase-2 (RIPK2) and nucleotide-binding oligomerization domain (NOD) cell signaling
  作者：Sameer Nikhar、Ioannis Siokas、Lisa Schlicher、Seungheon Lee、Mads Gyrd-Hansen、Alexei Degterev、Gregory D. Cuny

  DOI：10.1016/j.ejmech.2021.113252

  日期：2021.4

  implicated in numerous chronic inflammatory conditions. Herein, a pyrido[2,3-d]pyrimidin-7-one based class of RIPK2 kinase and NOD2 cell signaling inhibitors is described. For example, 33 (e.g. UH15–15) inhibited RIPK2 kinase (IC50 = 8 ± 4 nM) and displayed > 300-fold selectivity versus structurally related activin receptor-like kinase 2 (ALK2). This molecule blocked NOD2-dependent HEKBlue NF-κB activation

  受体相互作用蛋白激酶 2 (RIPK2) 是一种参与促炎核苷酸结合寡聚化结构域 (NOD) 细胞信号转导的酶，该信号通路与许多慢性炎症状况有关。本文描述了基于 pyrido[2,3-d]pyrimidin-7-one 的一类 RIPK2 激酶和 NOD2 细胞信号传导抑制剂。例如，33 (例如UH15 – 15 ) 抑制 RIPK2 激酶 (IC 50  = 8 ± 4 nM) 并显示出与结构相关的激活素受体样激酶 2 (ALK2) 相比 > 300 倍的选择性。该分子阻断 NOD2 依赖性 HEKBlue NF-κB 活化（IC 50 = 20 ± 5 nM）和 CXCL8 生产（浓度 > 10 nM）。分子对接表明，Ser25 在富含甘氨酸的环中的参与可能会提供比 ALK2 更高的选择性，并且守门员和 αC 螺旋之间区域的最佳占据可能有助于有效的 NOD2 细胞信号传导抑制。最后，该化合物还表现出良好的体外ADME
• Synthesis of Cyclopentenones through Rhodium-Catalyzed C–H Annulation of Acrylic Acids with Formaldehyde and Malonates
  作者：Shuling Yu、Chao Hong、Zhanxiang Liu、Yuhong Zhang

  DOI：10.1021/acs.orglett.1c01569

  日期：2021.7.2

  An efficient rhodium-catalyzed protocol for the synthesis of cyclopentenones based on a three-component reaction of acrylic acids, formaldehyde, and malonates via vinylic C–H activation is reported. Exploratory studies showed that 5-alkylation of as-prepared cyclopentenones could be realized smoothly by the treatment of a variety of alkyl halides with a Na2CO3/MeOH solution. Excess formaldehyde and

  报道了一种有效的铑催化合成环戊烯酮的方案，该方案基于丙烯酸、甲醛和丙二酸酯通过乙烯基 C-H 活化的三组分反应。探索性研究表明，通过用 Na 2 CO 3 /MeOH 溶液处理各种烷基卤化物，可以顺利地实现所制备的环戊烯酮的 5-烷基化。过量的甲醛和丙二酸酯导致多组分反应，通过迈克尔加成得到多取代的环戊烯酮。
• Three-component 2-aryl substituted benzothiophene formation under transition-metal free conditions
  作者：Pengcheng Jiang、Xingzong Che、Yunfeng Liao、Huawen Huang、Guo-Jun Deng

  DOI：10.1039/c6ra07730g

  日期：——

  A base-mediated 2-aryl substituted benzothiophene formation from 2-bromobenzene aldehydes, benzylic esters and elemental sulfur under transition-metal-free conditions is described. Various 2-aryl substituted benzothiophene were efficiently obtained under mild conditions.

  描述了在无过渡金属的条件下由2-溴苯醛，苄基酯和元素硫形成的碱介导的2-芳基取代的苯并噻吩。在温和的条件下有效地获得了各种2-芳基取代的苯并噻吩。
• [EN] SUBSTITUTED OXIMES, HYDRAZONES AND OLEFINS AS NEUROKININ ANTAGONISTS<br/>[FR] OXIMES, HYDRAZONES ET OLEFINES SUBSTITUEES, EN TANT QU'ANTAGONISTES DES NEUROKININES
  申请人：SCHERING CORPORATION

  公开号：WO1996034857A1

  公开（公告）日：1996-11-07

  (EN) Compound represented by structural formula (I) or a pharmaceutically acceptable salt thereof, wherein: a is 0, 1, 2 or 3; b, d and e are independently 0, 1 or 2; R is H, C1-6 alkyl, -OH or C2-C6 hydroxyalkyl; A is an optionally substituted oxime, hydrazone or olefin; X is a bond, -C(O)-, -O-, -NR6-, -S(O)e-, -N(R6)C(O)-, -C(O)N(R6)-, -OC(O)NR6-, -OC(=S)NR6-, -N(R6)C(=S)O-, -C(=NOR1)-, -S(O)2N(R6)-, -N(R6)S(O)2-, -N(R6)C(O)O- or -OC(O)-; T is H, phthalimidyl, aryl, heterocycloalkyl, heteroaryl, cycloalkyl or bridged cycloalkyl; Q is -SR6, -N(R6)(R7), -OR6, phenyl, naphthyl or heteroaryl; R6a, R7a, R8a, R9a, R6 and R7 are H, C1-6 alkyl, C2-C6 hydroxyalkyl, C1-C6 alkoxy-C1-C6 alkyl, phenyl or benzyl; or R6 and R7, together with the nitrogen to which they are attached, form a ring; R9a is R6 or -OR6; Z is morpholinyl, optionally N-substituted piperazinyl, optionally substituted (a), or substituted (b); g is 0-3 and h is 1-4, provided the sum of h and g is 1-7; wherein aryl, heterocycloalkyl, heteroaryl, cycloalkyl and bridged cycloalkyl groups are optionally substituted; methods of treating asthma, cough, bronchospasm, inflammatory diseases, and gastrointestinal disorders with said compounds, and pharmaceutical compositions comprising said compounds are disclosed.(FR) Composés représentés par la formule développée suivante (I), ou leur sel acceptable sur le plan pharmacologique. Dans cette formule, a vaut 0, 1, 2 ou 3; b, d et e valent indépendamment 0, 1 ou 2; R représente H, alkyle C1-6, -OH ou hydroxyalkyle C2-C6; A représente oxime, hydrazone ou oléfine, éventuellement substituée; X représente une liaison, -C(O)-, -O-, -NR6-, -S(O)e-, -N(R6)C(O)-, -C(O)N(R6)-, -OC(O)NR6-, -OC(=S)NR6-, -N(R6)C(=S)O-, -C(=NOR1)-, -S(O)2N(R6)-, -N(R6)S(O)2, -N(R6)C(O)O-, ou -OC(O)-; T représente H, phtalimidyle, aryle, hétérocycloalkyle, hétéroaryle, cycloalkyle ou cycloalkyle ponté; Q représente -SR6, -N(R6)(R7), -OR6, phényle, naphtyle ou hétéroaryle; R6a, R7a, R8a, R9a, R6 et R7 représentent H, alkyle C1-6, hydroxyalkyle C2-C6, alcoxy C1-C6-alkyle C1-C6, phényle ou benzyle; ou bien R6 et R7, ensemble avec l'azote auquel ils sont attachés, forment un noyau; R9a représente R6 ou -OR6; Z représente morpholinyle, pipérazinyle éventuellement N-substitué, (a) éventuellement substitué, ou (b) éventuellement substitué; g vaut 0 à 3 et h 1 à 4, à condition que la somme de h et de g représente 1 à 7; dans cette formule, les groupes aryle, hétérocycloalkyle, hétéroaryle, cycloalkyle et cycloalkyle ponté sont éventuellement substitués. On décrit encore des procédés de traitement de l'asthme, de la toux, du bronchospasme, des maladies inflammatoires et des troubles gastro-intestinaux à l'aide desdits composés, ainsi que des compositions pharmaceutiques contenant ceux-ci.

  化合物由结构式（I）或其药学上可接受的盐所表示，其中：a为0、1、2或3；b、d和e独立地为0、1或2；R为H、C1-6烷基、-OH或C2-C6羟基烷基；A为可选择取代的肟、腙或烯烃；X为键、-C（O）-、-O-、-NR6-、-S（O）e-、-N（R6）C（O）-、-C（O）N（R6）-、-OC（O）NR6-、-OC（=S）NR6-、-N（R6）C（=S）O-、-C（=NOR1）-、-S（O）2N（R6）-、-N（R6）S（O）2-、-N（R6）C（O）O-或-OC（O）-；T为H、邻苯二甲酰亚胺基、芳基、杂环烷基、杂芳基、环烷基或桥接环烷基；Q为-SR6、-N（R6）（R7）、-OR6、苯基、萘基或杂芳基；R6a、R7a、R8a、R9a、R6和R7为H、C1-6烷基、C2-C6羟基烷基、C1-C6烷氧基-C1-C6烷基、苯基或苄基；或R6和R7与它们连接的氮一起形成一个环；R9a为R6或-OR6；Z为吗啡啉基、可选择N取代的哌嗪基、可选择取代的（a）或取代的（b）；g为0-3，h为1-4，前提是h和g的总和为1-7；其中芳基、杂环烷基、杂芳基、环烷基和桥接环烷基基团可选择取代；揭示了使用该化合物治疗哮喘、咳嗽、支气管痉挛、炎症性疾病和胃肠障碍的方法，以及包含该化合物的药物组合物。
• Naphthalenone compounds exhibiting prolyl hydroxylase inhibitory activity, compositions, and uses thereof
  申请人：Allen Jennifer R.

  公开号：US20090093483A1

  公开（公告）日：2009-04-09

  Compounds of Formula I and Formula II are useful as inhibitors of HIF prolyl hydroxylases. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

  式I和式II的化合物可作为HIF脯氨酸羟化酶的抑制剂。式I和式II的化合物具有以下结构：其中变量的定义在此提供。